-
Reinventing Rexall Pharma Plus
It has been just over a year since Frank Scorpiniti took the helm at Canada's Rexall Pharma Plus. And, as the Canadian retail market continues to heat up, the company has officially taken the lid off a reinvention of its business, from its stores and its brand, to the products and services in its stores.
-
Report: Biosimilars could save $20 billion per year
While the Food and Drug Administration released draft guidance on regulations for biosimilars in February 2012, the final regulations have yet to appear. But already, everyone from analysts to trade groups to drug makers is preparing for a time when knock-off versions of biotech drugs will become available.
A new report sheds light on some of the opportunities and challenges that exist in follow-on biologics, arguing that their opportunity to generate value depends on factors like the speed of development, clarity of regulation, ease of access and the roles of all stakeholders.